Put companies on watchlist
PharmaSGP Holding SE
ISIN: DE000A2P4LJ5
WKN: A2P4LJ
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

PharmaSGP Holding SE · ISIN: DE000A2P4LJ5 · EQS - Company News (55 News)
Country: Germany · Primary market: Germany · EQS NID: 1318551
04 April 2022 07:30AM

PharmaSGP - Dividend at the upper end of the announced bandwidth after a record year in 2021


DGAP-News: PharmaSGP Holding SE / Key word(s): Dividend
PharmaSGP - Dividend at the upper end of the announced bandwidth after a record year in 2021

04.04.2022 / 07:30
The issuer is solely responsible for the content of this announcement.


PharmaSGP - Dividend at the upper end of the announced bandwidth after a record year in 2021

 

Gräfelfing, 04 April 2022 - At the end of February German OTC pharmaceuticals company PharmaSGP Holding SE (WKN: A2P4LJ) announced that the company had recorded a revenue record of € 65.3 million in financial year 2021 and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of € 19.4 million with significant growth of 14% year-on-year. Investors can now look forward to a dividend at the top end of the announced bandwidth of 30% to 50%. At the company's annual general meeting the management board will propose a dividend amounting to 50% of net income for the year.

"We are delighted that our investors will in this way be able to profit directly from our strong operating performance in the past year," CEO Natalie Weigand said. CFO Michael Rudolph added: "Thanks to our very high cash conversion rate of over 85%, we are in a position to take this step without at the same time restricting our scope for future investments."

In June of last year PharmaSGP acquired an OTC portfolio from pharmaceutical group GlaxoSmithKline which includes the Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R) brands. This in turn provided further momentum for growth in the fourth quarter of 2021, in addition to the positive development in organic business in the second half. The management board anticipates that following successful integration of the portfolio, its full potential will unfold in the current financial year.
 

CONTACT

cometis AG
Claudius Krause
Phone: 49-611-20585528
Email: ir@pharmasgp.com
 

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with the focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX(R) for rheumatic pain and Restaxil(R) for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R), thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe.

In 2021, PharmaSGP generated revenues of € 65.3 million at an adjusted EBITDA margin of 29.7%.

In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, increase PharmaSGP's European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.



04.04.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: PharmaSGP Holding SE
Lochhamer Schlag 21
82166 Gräfelfing
Germany
E-mail: ir@pharmasgp.com
Internet: https://pharmasgp.com
ISIN: DE000A2P4LJ5
WKN: A2P4LJ
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich
EQS News ID: 1318551

 
End of News DGAP News Service

1318551  04.04.2022 

fncls.ssp?fn=show_t_gif&application_id=1318551&application_name=news&site_id=boersengefluester_html
Visual performance / price development - PharmaSGP Holding SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.